Morphine News and Research

Latest Morphine News and Research

VA Federal Supply Schedule Service approves CTT as vendor for Calmare Pain Therapy Treatment

Competitive Technologies, Inc. announced today that the Department of Veterans Affairs' Federal Supply Schedule Service has accepted CTT's application to be an approved vendor for its Calmare® Pain Therapy Treatment. This decision will enable CTT to sell Calmare Pain Therapy to physicians throughout the Federal government, with the expectation of significant sales in that market sector, which includes the Department of Veterans Affairs, the Department of Defense, the Indian Health Service, the Bureau of Prisons, and State Veteran Homes.

15 Jun 2010

CTT's Calmare Pain Therapy Treatment shows promise against CIPN

Competitive Technologies, Inc. today announced the presentation of results from a study that shows the successful treatment of patients suffering from pain associated with chemotherapy-induced peripheral neuropathy using CTT's Calmare Pain Therapy Treatment. A three-hour discussion led by principal investigator, Thomas J. Smith, M.D., Endowed Chair of Palliative Care Research and Medical Director of the Thomas Palliative Care Unit Virginia Commonwealth University's Massey Cancer Center, at the American Society of Clinical Oncology Annual Meeting, cited results of the study.

11 Jun 2010

Unsatisfactory interactions with physicians affect sickle cell disease patients' trust in medical profession

Faculty at the Johns Hopkins Berman Institute of Bioethics have published a study that shows, among adults with sickle cell disease, that unsatisfactory interactions with health-care providers in the past affect their trust in the medical profession more broadly.

5 Jun 2010

Walter Reed Army Medical Center to treat pain patients with CTT's Calmare Pain Therapy Treatment

Competitive Technologies, Inc. announced today that the Walter Reed Army Medical Center in Washington, D.C., has joined the growing list of organizations that will treat pain patients with CTT's Calmare Pain Therapy Treatment, as authorized by the Surgeon General of the U.S. Army and Commanding General of the U.S. Army Medical Command.

5 Jun 2010

6th Research Congress of the EAPC reflects research in palliative care

The global interest for research in palliative care is increasing rapidly and The 6th Research Congress of the EAPC reflects this with a record number of abstracts and attendees -- more than 660 abstracts from 39 different countries will be presented to over 1200 international researchers and clinicians.

4 Jun 2010

Competitive Technologies to raise over $5M to accelerate sales of Calmare Pain Therapy Treatment

Competitive Technologies, Inc. today announced that it has signed an agreement to raise over $5 million by selling 2 million shares of equity to Crisnic Fund, S.A. based on a 15% discount from the volume weighted average price on the date the SEC declares the registration effective, as detailed in the 8-K being filed today.

2 Jun 2010

Study assesses possible links between pain medications and recurrent breast cancer risk

Women who receive one common pain drug during mastectomy are less likely to develop recurrent breast cancer in the years following surgery, suggests a study in the June issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

27 May 2010

CTT's Calmare Pain Therapy Treatment decreases pain associated with CIPN

Competitive Technologies, Inc. today announced the issuance of an abstract from a study which has shown the successful treatment of patients suffering from pain associated with chemotherapy-induced peripheral neuropathy using CTT's Calmare Pain Therapy Treatment.

21 May 2010

FDA approves ROXRO PHARMA's SPRIX Nasal Spray

ROXRO PHARMA, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved SPRIX™ (ketorolac tromethamine) Nasal Spray, for the short-term (up to 5 days) management of acute moderate to moderately severe pain that requires analgesia at the opioid level.

17 May 2010

Sucampo presents phase 3 trial results of lubiprostone in non-cancer pain patients with OBD at DDW 2010

Sucampo Pharmaceuticals, Inc. today announced the presentation of results from a phase 3 clinical trial investigating the use of lubiprostone in non-cancer pain patients with Opioid-induced Bowel Dysfunction (OBD). These results were the subject of an oral presentation at the Digestive Disease Week (DDW) 2010 conference in New Orleans, Louisiana, on May 5, 2010.

11 May 2010

Majority of Iraq and Afghanistan veterans experience multi-symptom pain disorders

Dr. Gallagher further noted the VA's pain care challenge is magnified by a 90 percent injury survivor rate from these conflicts compared with only 40 percent in the Vietnam War. VA clinicians are now challenged to manage pain in blast survivors with one or several other consequences of blast, such as head injuries causing mild to severe TBI, physical disfigurement and social stigma, emotional trauma, and often post traumatic stress disorder (PTSD).

10 May 2010

Additional pivotal Phase 3 trial data for MoxDuo IR released

QRxPharma announced today the release of additional pivotal Phase 3 trial data for MoxDuo IR, an immediate-release Dual-Opioid pain therapy. Required for New Drug Application submission with the United States Food and Drug Administration, this "combination rule" study compared the efficacy and safety profiles of MoxDuo IR against component doses of morphine and oxycodone alone for the management of moderate to severe post-operative pain following bunionectomy surgery.

5 May 2010

CocE exhibits potential for clinical treatment of cocaine toxicity

Cocaine toxicity due to drug overdose results in more than half a million emergency room visits annually. Despite these alarming statistics, there is no Food and Drug Administration-approved pharmacotherapy specifically designed to treat cocaine toxicity. Emergency medical personnel are limited to treating only the immediate life-threatening symptoms of patients, while toxic levels of cocaine and its metabolic break-down products persist and continue to damage the cardiovascular system, liver and brain.

27 Apr 2010

Stinging FDA review for Acurox – the implications

The US FDA’s advisory panel’s decision to recommend against approval of Acura Pharmaceuticals/King Pharmaceuticals’ Acurox (oxycodone plus niacin) was based upon the view that data were lacking that niacin-induced flushing could potentially reduce misuse of Acurox with single-ingredient oxycodone. The panel also contended that clinical studies were not conducted in populations that might be likely to benefit from the drug’s purported abuse-deterrent properties, such as those with chronic pain and adolescents who are experimenting with drug use.

27 Apr 2010

Spring fever not an official medical condition

In the season of ducklings, blooming dogwoods and open-toed sandals, some people are struck with a mysterious malady - spring fever.

24 Apr 2010

Calmare pain therapy medical device reviewed at CTT's annual meeting of shareholders

Competitive Technologies, Inc. held its annual meeting of shareholders today at the Hilton Stamford Hotel and Executive Meeting Center in Stamford, Conn. John B. Nano, CTT's Chairman, President and CEO reviewed the company's performance and highlighted the exciting progress on its sales and distribution plan for its Calmare pain therapy medical device, and other selected technologies.

20 Apr 2010

Ibuprofen demonstrates efficacy over acetaminophen for treatment of pain and fever

Cumberland Pharmaceuticals Inc. today announced results from a meta-analysis comparing the efficacy and safety of ibuprofen and acetaminophen, which was published in the March edition of the peer-reviewed journal The Annals of Pharmacotherapy. The publication notes that in a majority of evaluated studies ibuprofen demonstrated superior efficacy compared to acetaminophen for the treatment of pain and fever, and found no significant safety differences between the drugs.

15 Apr 2010

Phase II clinical study examining CTT's Calmare pain therapy medical device completed

Competitive Technologies, Inc. announced today that Thomas J. Smith, MD FACP, and co-investigator Patrick J. Coyne, MSN, APRN, FAAN, of Virginia Commonwealth University's Massey Cancer Center have completed their open Phase II clinical study examining CTT's Calmare pain therapy medical device's efficacy treating patients suffering with severe pain from chemotherapy induced peripheral neuropathy.

15 Apr 2010

Competitive Technologies to introduce Calmare pain therapy at medical conference

Competitive Technologies, Inc. announced today that it will hold a conference for the medical community on May 17, 2010, in Boston, Mass. at the Marriott Long Wharf Hotel from 9:00 a.m. to 3:30 p.m., to introduce CTT's Calmare® pain therapy to the medical community. Professor Giuseppe Marineo, MD, DSc., Researcher, Founding President of Delta Research and Development, Tor Vergata University of Rome, is the Italian inventor of the "Scrambler Therapy," the technology used in the Calmare medical device.

12 Apr 2010

Critical experts introduce mild exercise programs to care critically ill patients in ICU

A new report from critical care experts at Johns Hopkins shows that use of prescription sedatives goes down by half so that mild exercise programs can be introduced to the care of critically ill patients in the intensive care unit.

9 Apr 2010

Morphine News and Research

Latest Morphine News and Research

VA Federal Supply Schedule Service approves CTT as vendor for Calmare Pain Therapy Treatment

CTT's Calmare Pain Therapy Treatment shows promise against CIPN

Unsatisfactory interactions with physicians affect sickle cell disease patients' trust in medical profession

Walter Reed Army Medical Center to treat pain patients with CTT's Calmare Pain Therapy Treatment

6th Research Congress of the EAPC reflects research in palliative care

Competitive Technologies to raise over $5M to accelerate sales of Calmare Pain Therapy Treatment

Study assesses possible links between pain medications and recurrent breast cancer risk

CTT's Calmare Pain Therapy Treatment decreases pain associated with CIPN

FDA approves ROXRO PHARMA's SPRIX Nasal Spray

Sucampo presents phase 3 trial results of lubiprostone in non-cancer pain patients with OBD at DDW 2010

Majority of Iraq and Afghanistan veterans experience multi-symptom pain disorders

Additional pivotal Phase 3 trial data for MoxDuo IR released

CocE exhibits potential for clinical treatment of cocaine toxicity

Stinging FDA review for Acurox – the implications

Spring fever not an official medical condition

Calmare pain therapy medical device reviewed at CTT's annual meeting of shareholders

Ibuprofen demonstrates efficacy over acetaminophen for treatment of pain and fever

Phase II clinical study examining CTT's Calmare pain therapy medical device completed

Competitive Technologies to introduce Calmare pain therapy at medical conference

Critical experts introduce mild exercise programs to care critically ill patients in ICU

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Morphine News and Research

Latest Morphine News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in